Application

For research use only. Not for use in diagnostic procedures.Please refer to the attached General ELISA KIT Procedure (sandwich, competitive & Indirect ELISA)

Biochem/physiol Actions

Binding of soluble osteoprotegerin (OPG) to sRANKL (soluble receptor activator of nuclear factor κ-B ligand) inhibits osteoclastogenesis by interrupting the signaling between stromal cells and osteoclastic progenitor cells. This process leads to excess accumulation of bone and cartilage. Changes in the level of serum OPG are associated with atherosclerosis and cardiovascular disorders(CVDs). It might also be associated with malignancy and plays a regulatory role in multiple myeloma, prostate, breast, bladder and gastric carcinoma. OPG plays a vital role in bone metabolism and is involved in inhibition of ovariectomy-associated bone loss in rats. It is also used as a potent biomarker for CVD.

General description

The Human Osteoprotegerin ELISA (Enzyme-Linked Immunosorbent Assay) kit is an in vitro enzyme-linked immunosorbent assay for the quantitative measurement of human Osteoprotegerin in serum, plasma, cell culture supernatants and urine.Osteoprotegerin (OPG) is encoded by the gene mapped to human chromosome 8q24. It is a member of the TNFR (tumor necrosis factor receptor) superfamily that can act as a decoy receptor for RANKL (receptor activator of nuclear factor kappa-B ligand) and TRAIL (tumor necrosis factor-related apoptosis-inducing ligand). OPG is expressed in a wide variety of tissues, including adult heart, lung, kidney and liver. It is secreted both as a monomeric and a dimeric protein.

Immunogen

Recombinant Human OPG

Other Notes

A sample Certificate of Analysis is available for this product.Please type the word sample in the text box provided for lot number.